Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Slideshows|July 20, 2017
6 Ways to Reduce No-Shows (and Save Lives)
Author(s)Chris Aiken, MD
Not just a nuisance, no-shows are an opportunity to turn things around for patients with bipolar disorder, whose treatment adherence hovers around 60%.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
2
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
3
From Side Effect to Target: Rethinking Metabolic Dysfunction in Psychiatry
4
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
5